AbbVie Clinical Trial Shows Promising Results for Crohn's Disease Combination Therapy
AbbVie (ABBV) is developing a potential new blockbuster drug, ABBV-466, which combines its existing treatment Skyrizi with a second antibody, trosunilimab. In Phase 2 clinical studies for Crohn's disease, the combination therapy significantly outperformed monotherapy in achieving endoscopic remission. At week 24, 40.5% of patients on the combination reached remission, compared to approximately 20-22% for those using Skyrizi or trosunilimab alone. While serious adverse events were slightly higher in the combination group (10.4%) than in monotherapy groups, analysts from BMO Capital Markets and RBC Capital Markets view the results as a significant win for AbbVie's lifecycle management. The dual-targeting approach aims to block multiple inflammatory pathways, potentially establishing a durable competitive moat in the Inflammatory Bowel Disease (IBD) market.
Topics: biotechnology clinical trial results Crohn's disease drug development